NC
IMGN

Nexthera Capital’s Immunogen Inc IMGN Stock Holding History

Nexthera Capital’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-140,500
Closed -$433K – 40
2016
Q2 		$433K Sell
140,500
-87,500
-38% -$549K 0.37% 31
2016
Q1 		$1.94M Buy
+228,000
New +$1.93M 2.01% 13

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nexthera Capital's IMGN Position: Q3 2016 in Review

Nexthera Capital sold out of Immunogen Inc (IMGN) in Q3 2016, closing a stake of 140,500 shares — an estimated $433K sold.

Nexthera Capital first reported a position in IMGN in Q1 2016 and held it in 2 quarters. The position peaked at $1.94M in Q1 2016. 155 funds tracked by Wall St. Rank hold IMGN as of Q3 2016.

  • Nexthera Capital reported no remaining Immunogen Inc position as of Q3 2016 after selling out during the quarter.
  • Nexthera Capital sold 140,500 Immunogen Inc shares in Q3 2016, an estimated $433K.
  • Nexthera Capital first reported a position in Immunogen Inc in Q1 2016 and held it in 2 quarters.
  • Nexthera Capital's Immunogen Inc position peaked at $1.94M in Q1 2016.
  • 155 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2016.

Based on Nexthera Capital's 13F filing for Q3 2016, filed 14 Nov 2016.